Answer
Stomatitis was reported in 71.8% of the 255 patients receiving Vizimpro (dacomitinib monohydrate) in pooled clinical safety data, with 45 mg once daily as the starting dose for first-line treatment of NSCLC with EGFR-activating mutations.
Sources for this answer
- Vizimpro 15mg film-coated tabletsPfizer Limited · emc · SmPC §4.8 Undesirable effects · Version 5Document updated
Sources checked